True Wealth Design LLC Buys 153 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

True Wealth Design LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 15,300.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 154 shares of the biopharmaceutical company’s stock after purchasing an additional 153 shares during the quarter. True Wealth Design LLC’s holdings in Alnylam Pharmaceuticals were worth $42,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Diversified Trust Co bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $1,210,000. Los Angeles Capital Management LLC raised its stake in shares of Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after buying an additional 135,829 shares during the last quarter. Breakwater Capital Group acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $249,000. Sanctuary Advisors LLC bought a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Alnylam Pharmaceuticals by 22.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after acquiring an additional 13,422 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $422,148.36. Following the sale, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,370 shares of company stock worth $2,100,703 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and set a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a “neutral” rating in a report on Monday, August 26th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $253.07 on Monday. The stock has a market capitalization of $32.64 billion, a price-to-earnings ratio of -96.59 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The firm has a fifty day simple moving average of $271.07 and a 200 day simple moving average of $241.66. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. Alnylam Pharmaceuticals’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 EPS. Research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.